Diagonal Bio AB (DIABIO) — Cash Flow-to-Debt Ratio
Diagonal Bio AB (DIABIO) has a Cash Flow-to-Debt Ratio of -1.07x as of September 2025, meaning its operating cash flow of Skr-2.27 Million could theoretically repay -1% of its total liabilities (Skr2.13 Million) in one year. See DIABIO FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Diagonal Bio AB Cash Flow-to-Debt Ratio (2020–2024)
Historical debt coverage capacity for Diagonal Bio AB across 5 annual periods. Also explore net asset growth rate of Diagonal Bio AB to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Diagonal Bio AB (2020–2024)
Year-by-year debt coverage analysis for Diagonal Bio AB. For market capitalisation and broader financial context, see Diagonal Bio AB (DIABIO) total market value.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -5.42x | Skr-13.77 Million | Skr2.54 Million | ▼ -652.5% |
| 2023 | -0.72x | Skr-5.23 Million | Skr7.26 Million | ▲ +87.3% |
| 2022 | -5.68x | Skr-15.77 Million | Skr2.78 Million | ▼ -11.3% |
| 2021 | -5.10x | Skr-10.94 Million | Skr2.14 Million | ▼ -2531.9% |
| 2020 | 0.21x | Skr226.67K | Skr1.08 Million | — |